Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.

tumours have dismal outcomes and are enriched in chemotherapy-sensitive but ET- and palbociclib-resistant tumours. Biomarker analysis and clinical data suggest a potential role for immunotherapy in this group.